Art

J-GLOBAL ID：201602291478901189   Reference number：16A0814874

Rituximab treatment for relapsed opsoclonus-myoclonus syndrome

再発オプソクローヌス-ミオクローヌス症候群に対するリツキシマブ治療

Author (12)： Toyoshima Daisaku (Department of Pediatrics, Kobe University Graduate School of Medicine, Japan) ,  Morisada Naoya (Department of Pediatrics, Kobe University Graduate School of Medicine, Japan) ,  Takami Yuichi (Department of Pediatrics, Himeji Red Cross Hospital, Japan) ,  Kidokoro Hiroyuki (Department of Pediatrics, Nagoya University Graduate School of Medicine, Japan) ,  Nishiyama Masahiro (Department of Pediatrics, Kobe University Graduate School of Medicine, Japan) ,  Nakagawa Taku (Department of Pediatrics, Himeji Red Cross Hospital, Japan) ,  Ninchoji Takeshi (Department of Pediatrics, Kobe University Graduate School of Medicine, Japan) ,  Nozu Kandai (Department of Pediatrics, Kobe University Graduate School of Medicine, Japan) ,  Takeshima Yasuhiro (Department of Pediatrics, Hyogo College of Medicine, Japan) ,  Takada Satoshi (Kobe University Graduate School of Health Science, Japan) ,  Nishio Hisahide (Division of Epidemiology, Kobe University Graduate School of Medicine, Japan) ,  Iijima Kazumoto (Department of Pediatrics, Kobe University Graduate School of Medicine, Japan)
Material： Brain & Development  (Brain & Dev)
Volume： 38  Issue： 3  Page： 346-349  Publication year： Mar. 2016 
JST Material Number： W0814A  ISSN： 0387-7604  Document type： Article
Article type： 原著論文  Country of issue： Netherlands (NLD)  Language： ENGLISH (EN)

Thesaurus term： ocular motility disorder ,...
Semi thesaurus term： *Opsoclonus-Myoclonus Syndrome ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=16A0814874&from=J-GLOBAL&jstjournalNo=W0814A") }}

Author keywords (4)： Opsoclonus-myoclonus syndrome ,  Rituximab ,  Single dose ,  Neuroblastoma

JST classification (2)： Clinical application of immunotherapeutic agents and blood preparations  (GW22020O) ,  Drug therapy(=pharmacotherapy)for nervous system diseases  (GN05020Y)

Reference (10)：

• Kinsbourne M. Myoclonic encephalopathy of infants. J Neurol Neurosurg Psychiatry 1962;25:271-6.
• Hasegawa S, Matsushige T, Kajimoto M, Inoue H, Momonaka H, Oka M, et al. A nationwide survey of opsoclonus-myoclonus syndrome in Japanese children. Brain Dev 2015;37:656-60.
• Brunklaus A, Pohl K, Zuberi SM, de Sousa C. Outcome and prognostic features in opsoclonus-myoclonus syndrome from infancy to adult life. Pediatrics 2011;128:e388-94.
• Mitchell WG, Wooten AA, O'Neil SH, Rodriguez JG, Cruz RE, Wittern R. Effect of Increased Immunosuppression on developmental outcome of opsoclonus myoclonus syndrome (OMS). J Child Neurol 2015;30:976-82.
• Pranzatelli MR, Tate ED, Travelstead AL, Longee D. Immunologic and clinical responses to rituximab in a child with opsoclonus-myoclonus syndrome. Pediatrics 2005;115:e115-9.

Terms in the title (4)： 再発 ,  オプソクローヌス-ミオクローヌス症候群 ,  リツキシマブ ,  治療